BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Won JK, Yu SJ, Hwang CY, Cho SH, Park SM, Kim K, Choi WM, Cho H, Cho EJ, Lee JH, Lee KB, Kim YJ, Suh KS, Jang JJ, Kim CY, Yoon JH, Cho KH. Protein disulfide isomerase inhibition synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma. Hepatology 2017;66:855-68. [PMID: 28439950 DOI: 10.1002/hep.29237] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 4.4] [Reference Citation Analysis]
Number Citing Articles
1 Fishbein A, Wang W, Yang H, Yang J, Hallisey VM, Deng J, Verheul SML, Hwang SH, Gartung A, Wang Y, Bielenberg DR, Huang S, Kieran MW, Hammock BD, Panigrahy D. Resolution of eicosanoid/cytokine storm prevents carcinogen and inflammation-initiated hepatocellular cancer progression. Proc Natl Acad Sci U S A 2020;117:21576-87. [PMID: 32801214 DOI: 10.1073/pnas.2007412117] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
2 Tang X, Chen L, Li A, Cai S, Zhang Y, Liu X, Jiang Z, Liu X, Liang Y, Ma D. Anti-GPC3 antibody-modified sorafenib-loaded nanoparticles significantly inhibited HepG2 hepatocellular carcinoma. Drug Deliv 2018;25:1484-94. [PMID: 29916268 DOI: 10.1080/10717544.2018.1477859] [Cited by in Crossref: 24] [Cited by in F6Publishing: 29] [Article Influence: 6.0] [Reference Citation Analysis]
3 Cheng Z, Wei-Qi J, Jin D. New insights on sorafenib resistance in liver cancer with correlation of individualized therapy. Biochim Biophys Acta Rev Cancer 2020;1874:188382. [PMID: 32522600 DOI: 10.1016/j.bbcan.2020.188382] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
4 Xu S, Liu Y, Yang K, Wang H, Shergalis A, Kyani A, Bankhead A 3rd, Tamura S, Yang S, Wang X, Wang CC, Rehemtulla A, Ljungman M, Neamati N. Inhibition of protein disulfide isomerase in glioblastoma causes marked downregulation of DNA repair and DNA damage response genes. Theranostics 2019;9:2282-98. [PMID: 31149044 DOI: 10.7150/thno.30621] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
5 Shao Z, Li Y, Dai W, Jia H, Zhang Y, Jiang Q, Chai Y, Li X, Sun H, Yang R, Cao Y, Feng F, Guo Y. ETS-1 induces Sorafenib-resistance in hepatocellular carcinoma cells via regulating transcription factor activity of PXR. Pharmacol Res 2018;135:188-200. [PMID: 30114438 DOI: 10.1016/j.phrs.2018.08.003] [Cited by in Crossref: 30] [Cited by in F6Publishing: 48] [Article Influence: 7.5] [Reference Citation Analysis]
6 Zhu Z, Xu L, Zhuang L, Ning Z, Zhang C, Yan X, Lin J, Shen Y, Wang P, Meng Z. Role of monocyte-to-lymphocyte ratio in predicting sorafenib response in patients with advanced hepatocellular carcinoma. Onco Targets Ther. 2018;11:6731-6740. [PMID: 30349306 DOI: 10.2147/ott.s173275] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
7 Yang PM, Lin LS, Liu TP. Sorafenib Inhibits Ribonucleotide Reductase Regulatory Subunit M2 (RRM2) in Hepatocellular Carcinoma Cells. Biomolecules 2020;10:E117. [PMID: 31936661 DOI: 10.3390/biom10010117] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 9.0] [Reference Citation Analysis]
8 Zhang S, Wang D, Li Y, Li L, Chen H, Xiong Q, Liu Y, Wang Y. pH- and redox-responsive nanoparticles composed of charge-reversible pullulan-based shells and disulfide-containing poly( ß -amino ester) cores for co-delivery of a gene and chemotherapeutic agent. Nanotechnology 2018;29:325101. [DOI: 10.1088/1361-6528/aac4b5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
9 Lippolis R, Gnocchi D, Santacroce L, Siciliano RA, Mazzeo MF, Scacco S, Sabbà C, Mazzocca A. A distinctive protein signature induced by lysophosphatidic acid receptor 6 (LPAR6) expression in hepatocellular carcinoma cells. Biochem Biophys Res Commun 2020;526:1150-6. [PMID: 32321639 DOI: 10.1016/j.bbrc.2020.04.036] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Hu B, Cheng JW, Hu JW, Li H, Ma XL, Tang WG, Sun YF, Guo W, Huang A, Zhou KQ, Gao PT, Cao Y, Qiu SJ, Zhou J, Fan J, Yang XR. KPNA3 Confers Sorafenib Resistance to Advanced Hepatocellular Carcinoma via TWIST Regulated Epithelial-Mesenchymal Transition. J Cancer 2019;10:3914-25. [PMID: 31417635 DOI: 10.7150/jca.31448] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
11 Joo JI, Choi M, Jang SH, Choi S, Park SM, Shin D, Cho KH. Realizing Cancer Precision Medicine by Integrating Systems Biology and Nanomaterial Engineering. Adv Mater 2020;32:e1906783. [PMID: 32253807 DOI: 10.1002/adma.201906783] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
12 Chipurupalli S, Kannan E, Tergaonkar V, D'Andrea R, Robinson N. Hypoxia Induced ER Stress Response as an Adaptive Mechanism in Cancer. Int J Mol Sci 2019;20:E749. [PMID: 30754624 DOI: 10.3390/ijms20030749] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 10.3] [Reference Citation Analysis]
13 Hwang CY, Yu SJ, Won JK, Park SM, Noh H, Lee S, Cho EJ, Lee JH, Lee KB, Kim YJ, Suh KS, Yoon JH, Cho KH. Systems analysis identifies endothelin 1 axis blockade for enhancing the anti-tumor effect of multikinase inhibitor. Cancer Gene Ther 2021. [PMID: 34363028 DOI: 10.1038/s41417-021-00373-x] [Reference Citation Analysis]
14 Liu X, Zhang Y, Lu W, Han Y, Yang J, Jiang W, You X, Luo Y, Wen S, Hu Y, Huang P. Mitochondrial TXNRD3 confers drug resistance via redox-mediated mechanism and is a potential therapeutic target in vivo. Redox Biol 2020;36:101652. [PMID: 32750669 DOI: 10.1016/j.redox.2020.101652] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
15 Zhang H, Zhong WL, Sun B, Yang G, Liu YR, Zhou BJ, Chen X, Jing XY, Huai LC, Liu N, Zhang ZY, Li MM, Han JX, Qiao KL, Meng J, Zhou HG, Chen S, Yang C, Sun T. Targeted Drug-Loaded Chemical Probe Staining Assay to Predict Therapy Response and Function as an Independent Pathological Marker. iScience 2019;21:549-61. [PMID: 31715498 DOI: 10.1016/j.isci.2019.10.050] [Reference Citation Analysis]
16 Chlebowska-Tuz J, Sokolowska O, Gaj P, Lazniewski M, Firczuk M, Borowiec K, Sas-Nowosielska H, Bajor M, Malinowska A, Muchowicz A, Ramji K, Stawinski P, Sobczak M, Pilch Z, Rodziewicz-Lurzynska A, Zajac M, Giannopoulos K, Juszczynski P, Basak GW, Plewczynski D, Ploski R, Golab J, Nowis D. Inhibition of protein disulfide isomerase induces differentiation of acute myeloid leukemia cells. Haematologica 2018;103:1843-52. [PMID: 30002127 DOI: 10.3324/haematol.2018.190231] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
17 Jha V, Kumari T, Manickam V, Assar Z, Olson KL, Min JK, Cho J. ERO1-PDI Redox Signaling in Health and Disease. Antioxid Redox Signal 2021. [PMID: 34074138 DOI: 10.1089/ars.2021.0018] [Reference Citation Analysis]
18 Lebeaupin C, Vallée D, Hazari Y, Hetz C, Chevet E, Bailly-Maitre B. Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease. J Hepatol 2018;69:927-47. [PMID: 29940269 DOI: 10.1016/j.jhep.2018.06.008] [Cited by in Crossref: 198] [Cited by in F6Publishing: 195] [Article Influence: 49.5] [Reference Citation Analysis]
19 Wang Y, Tang Z. A novel long-sustaining system of apatinib for long-term inhibition of the proliferation of hepatocellular carcinoma cells. Onco Targets Ther 2018;11:8529-41. [PMID: 30555243 DOI: 10.2147/OTT.S188209] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
20 Lin X, Li AM, Li YH, Luo RC, Zou YJ, Liu YY, Liu C, Xie YY, Zuo S, Liu Z, Liu Z, Fang WY. Silencing MYH9 blocks HBx-induced GSK3β ubiquitination and degradation to inhibit tumor stemness in hepatocellular carcinoma. Signal Transduct Target Ther 2020;5:13. [PMID: 32296025 DOI: 10.1038/s41392-020-0111-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 10.5] [Reference Citation Analysis]
21 Ocklenburg T, Neumann F, Wolf A, Vogel J, Göpelt K, Baumann M, Baumann J, Kranz P, Metzen E, Brockmeier U. In oxygen-deprived tumor cells ERp57 provides radioprotection and ensures proliferation via c-Myc, PLK1 and the AKT pathway. Sci Rep 2021;11:7199. [PMID: 33785835 DOI: 10.1038/s41598-021-86658-5] [Reference Citation Analysis]
22 Shergalis A, Xue D, Gharbia FZ, Driks H, Shrestha B, Tanweer A, Cromer K, Ljungman M, Neamati N. Characterization of Aminobenzylphenols as Protein Disulfide Isomerase Inhibitors in Glioblastoma Cell Lines. J Med Chem 2020;63:10263-86. [PMID: 32830969 DOI: 10.1021/acs.jmedchem.0c00728] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
23 Zwicker JI, Schlechter BL, Stopa JD, Liebman HA, Aggarwal A, Puligandla M, Caughey T, Bauer KA, Kuemmerle N, Wong E, Wun T, McLaughlin M, Hidalgo M, Neuberg D, Furie B, Flaumenhaft R; CATIQ Investigators11. Targeting protein disulfide isomerase with the flavonoid isoquercetin to improve hypercoagulability in advanced cancer. JCI Insight 2019;4:125851. [PMID: 30652973 DOI: 10.1172/jci.insight.125851] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 13.0] [Reference Citation Analysis]
24 Tong Z, Zhou Y, Wang J. Identifying potential drug targets in hepatocellular carcinoma based on network analysis and one-class support vector machine. Sci Rep 2019;9:10442. [PMID: 31320657 DOI: 10.1038/s41598-019-46540-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]